
Strategic clinical research leader with over 10 years in clinical development and 6 years in pharmaceutical leadership. Expertise in directing global late and early oncology R&D programs, focusing on small molecule inhibitors, ADCs, and immuno-oncology. Proven ability to drive clinical strategy, regulatory alignment, and innovative trial designs, ensuring effective dosing strategies and compliance. Track record of steering complex global programs to achieve decisive milestones with operational excellence.